A robust multicenter study led by the IVY Network demonstrates that a single shot of the respiratory syncytial virus (RSV) vaccine provides significant protection against severe RSV illness and hospitalization in older adults across two consecutive seasons. Published recently in JAMA, the findings emphasize the vaccine's durable efficacy, offering a critical tool in managing RSV burden among an aging population.